Literature DB >> 24286586

Heart failure with preserved ejection fraction: an ongoing enigma.

Lisa J Rose-Jones1, John J Rommel, Patricia P Chang.   

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a complex clinical syndrome based on traditional heart failure symptoms with documentation of increased left ventricular filling pressures and preserved left ventricular ejection fraction. The exact mechanisms that induce HFpEF are not known. End-diastolic ventricular stiffness does not seem to be acting alone. Substantial mortality exists compared with healthy age-matched controls, as well as significant health care expenditures on hospitalizations and readmissions. This article reviews the epidemiology, pathophysiology, and treatment of heart failure with preserved ejection fraction (HFpEF). Current practice guidelines focus on remedying volume overload, aggressively controlling hypertension, and treatment of comorbid conditions that contribute to decompensation.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diastolic dysfunction; HFpEF; Heart failure; Preserved ejection fraction; Review

Mesh:

Substances:

Year:  2014        PMID: 24286586     DOI: 10.1016/j.ccl.2013.09.006

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN: 0733-8651            Impact factor:   2.213


  7 in total

1.  Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction.

Authors:  Fernando Friões; Patrícia Lourenço; Olga Laszczynska; Pedro-Bernardo Almeida; João-Tiago Guimarães; James L Januzzi; Ana Azevedo; Paulo Bettencourt
Journal:  Clin Res Cardiol       Date:  2015-01-14       Impact factor: 5.460

Review 2.  Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond.

Authors:  Jagdeep S S Singh; Chim C Lang
Journal:  Vasc Health Risk Manag       Date:  2015-06-01

3.  A Feline HFpEF Model with Pulmonary Hypertension and Compromised Pulmonary Function.

Authors:  Markus Wallner; Deborah M Eaton; Remus M Berretta; Giulia Borghetti; Jichuan Wu; Sandy T Baker; Eric A Feldsott; Thomas E Sharp; Sadia Mohsin; Mark A Oyama; Dirk von Lewinski; Heiner Post; Marla R Wolfson; Steven R Houser
Journal:  Sci Rep       Date:  2017-11-29       Impact factor: 4.379

Review 4.  Hypertension-induced remodelling: on the interactions of cardiac risk factors.

Authors:  Jakub Tomek; Gil Bub
Journal:  J Physiol       Date:  2017-03-30       Impact factor: 5.182

5.  Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model.

Authors:  Moa P Lee; Robert J Glynn; Sebastian Schneeweiss; Kueiyu Joshua Lin; Elisabetta Patorno; Julie Barberio; Raisa Levin; Thomas Evers; Shirley V Wang; Rishi J Desai
Journal:  Clin Epidemiol       Date:  2020-06-15       Impact factor: 4.790

Review 6.  Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic Review.

Authors:  Ambarish Pandey; Sushil Garg; Susan A Matulevicius; Amil M Shah; Jalaj Garg; Mark H Drazner; Alpesh Amin; Jarett D Berry; Thomas H Marwick; Steven P Marso; James A de Lemos; Dharam J Kumbhani
Journal:  J Am Heart Assoc       Date:  2015-10-12       Impact factor: 5.501

7.  Twist/untwist parameters are promising evaluators of myocardial mechanic changes in heart failure patients with preserved ejection fraction.

Authors:  Yi Zhang; Shen-Yi Li; Juan-Juan Xie; Yuan Wu
Journal:  Clin Cardiol       Date:  2020-03-25       Impact factor: 2.882

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.